ReviewFrontiers in pharmacology2026
Computer-aided drug discovery: historical foundations, practical AI tools, and emerging ethical considerations.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Computer-aided drug discovery (CADD) has become an integral component of modern drug development, supporting hit identification, lead optimisation, and candidate refinement across both academia and industry. Over 4 decades of methodological progress have contributed to the discovery or optimisation of several approved therapeutics, establishing CADD as a crucial element of drug research. In parallel, recent advances in artificial intelligence (AI) and machine learning (ML) have introduced a new generation of practical tools that offer improved predictive performance, accessible software implementations, and increasing integration into everyday drug discovery and pharmacology workflows. This review provides a concise historical overview of CADD, with an updated account of approved drugs and clinical-stage candidates whose discovery or optimisation has involved computational methods and highlights a curated set of contemporary AI and ML tools that are readily usable by non-specialists. In addition, we compile and analyse two comprehensive, practice-oriented resources: a collection of cloud-based virtual-screening platforms, and an extensive suite of freely accessible ADMET prediction tools, offering medicinal chemists a consolidated guide to open-source computational workflows. Finally, we discuss emerging ethical considerations, including data bias, transparency, computational costs, and the environmental impact of large-scale models, outlining responsible paths for the continued adoption of AI in drug discovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.